IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC
Completed
The purpose of this study is to determine if IO102 combined with pembrolizumab with or without chemotherapy is safe tolerable and effective in the treatment of Non-small Cell Lung Carcinoma (NSCLC). The hypothesis is that IO102 will improve the objective response rate (ORR) in patients with metastatic NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/20/2022
Locations: Thoraxklinik Heidelberg gGmbH, Heidelberg, Community Of Heidelberg +12 locations
Conditions: NSCLC
International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma
Active Not Recruiting
The study PNET 5 MB has been designed for children with medulloblastoma of standard risk (according to the risk-group definitions which have been used so far; e.g. in PNET 4). With the advent of biological parameters for stratification into clinical medulloblastoma trials, the ß-catenin status will be the only criterion according to which study patients will be assigned to either treatment arm PNET 5 MB - LR or to PNET 5 MB - SR, respectively. The initial diagnostic assessments (imaging, staging... Read More
Gender:
ALL
Ages:
Between 3 years and 21 years
Trial Updated:
04/11/2022
Locations: Medical University of Graz, Graz, Not set +76 locations
Conditions: Brain Tumors
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Completed
The purpose of the study is to estimate the response rate and compare overall survival of patients taking BMS-936558 to those taking study physician's choice of either Dacarbazine or Carboplatin and Paclitaxel
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/23/2022
Locations: Mayo Clinic, Phoenix, Arizona +94 locations
Conditions: Unresectable or Metastatic Melanoma
An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease
Withdrawn
The purpose of this study is to determine if nivolumab added to the standard of care therapy (SOC) given after surgery is more effective than SOC alone in prolonging disease free survival in NSCLC participants with minimal residual disease detected after surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/09/2022
Locations: Local Institution, Jacksonville, Florida +12 locations
Conditions: Non-Small Cell Lung Cancer, Non-Small-Cell Lung Carcinoma, Circulating Tumor DNA
INOVATYON STUDY -International, Randomized Study in Patients With Ovarian Cancer
Completed
The objective of this multicentric, randomised, Phase III study is to demonstrate superiority, in terms of survival, of trabectedin and Pegylated Liposomal Doxorubicin (PLD) versus carboplatin and PLD in partially-platinum sensitive ovarian cancer patients.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/08/2022
Locations: Krankenhaus Der Barmherzigen Brueder, Graz, AT +131 locations
Conditions: Ovarian Cancer
Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer
Completed
This is a randomized, open-label, multi-center, 3-arm, global Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination or MEDI4736 monotherapy versus SoC (EXTREME regimen) in the treatment of patients with SCCHN who have not received prior systemic chemotherapy for recurrent or metastatic disease.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
09/16/2021
Locations: Research Site, Aurora, Colorado +196 locations
Conditions: Squamous Cell Carcinoma of the Head and Neck
Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer
Completed
Evaluation of the best therapeutic index for patients with platinum-sensitive ovarian cancer when treatment with bevacizumab and gemcitabine/carboplatin or with bevacizumab and PLD/carboplatin.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/08/2021
Locations: Bankstown-Lidcombe Hospital, Bankstown, Not set +192 locations
Conditions: Recurrent Platinum-sensitive Ovarian Cancer
Safety and Efficacy Study of Nuc-1031 and Carboplatin Combination to Treat Recurrent Ovarian Cancer
Completed
A first in human experimental treatment in which an experimental medicine,Nuc-1031, is used in combination with a standard cancer medicine, carboplatin, to treat ovarian cancer which reappear after standard cancer treatment. The aim of the trial is to determine safety, effectiveness, and clinical activity of this combination treatment.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/17/2021
Locations: Garry Weston Cancer Centre, Hammersmith Hospital, London, Not set
Conditions: Recurrent Ovarian Cancer
Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer
Terminated
The purpose of this study is to evaluate the safety, immunogenicity and clinical activity of a new WT1 anti-cancer immunotherapy in patients with WT1-positive Stage II or III breast cancer. The treatment will be given before surgery in combination with standard therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2021
Locations: GSK Investigational Site, Newark, Delaware +35 locations
Conditions: Neoplasms, Breast
STUDY 15 - Comparing Gemcitabine/Carboplatin and Hydroxychloroquine Versus Carboplatin/Etoposide Therapy Alone in Small Cell Lung Cancer (SCLC)
Terminated
To determine whether the combination of gemcitabine/carboplatin with hydroxychloroquine (HCQ) is associated with an improved clinical outcome (progression free and overall survival) compared with chemotherapy alone in patients with small cell lung cancer (SCLC)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/16/2021
Locations: Dorset County Hospital NHS Foundation Trust, Dorchester, Not set +12 locations
Conditions: Small Cell Lung Cancer
Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers
Completed
The purpose of this study is to evaluate the safety and efficacy of veliparib plus carboplatin and paclitaxel versus the Investigator's choice of standard chemotherapy in adults with metastatic or advanced non-squamous non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/08/2021
Locations: Clearview Cancer Institute /ID# 131434, Huntsville, Alabama +139 locations
Conditions: Non-squamous Non-small Cell Lung Cancer
Carboplatin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Terminated
RATIONALE: Drugs used in chemotherapy, such as carboplatin and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving carboplatin together with gemcitabine works in treating patients with locally advanced or metastatic breast cancer.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
01/29/2021
Locations: Royal Bournemouth Hospital, Bournemouth, England +2 locations
Conditions: Breast Cancer